

Substitute for FORM 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Filing Date: July 2, 2003

First Named Inventor: Byron E. Anderson

Group Art Unit: 1639

Confirmation Number: 5133

Application Number:

(Use as many sheets as necessary)

Sheet 1 of 1

Examiner Name: Gross, Christopher M. Attorney Docket Number: 45240-105719

Complete if Known

10/612,298

1
n Filing Date Appropriate
01

				FORE	IGN PATENT DOCUMENTS			
		Foreign Patent Document				Translation		
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
	33	WO	94/26296		Houghten Pharmaceuticals, Inc.	Nov. 24, 1994		
	34	WO	01/39796	A2	Neurochem Inc.	June 7, 2001		

		OTHER - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.		No*+
	35	Kundu et al., "Combinatorial Approach to Lead Optimization of a Novel Hexapeptide with Antifungal Activity," <i>Bioorganic & Medicinal Chemistry Letters</i> , 10 (16): 1779-1781 (2000).		
	36	Copy of Supplementary Partial European Search Report issued in EP 03 76 3093 (2008).		
				-

CHDS01 AOM 463552v1

EXAMINER DATE CONSIDERED

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3)